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Methods: Patients in a randomized phase III study conducted in 
western patients (Study-W1) received PEM 500mgm2 or 900mg/m2 
once every 3 weeks. Patients enrolled in a randomized phase II study 
conducted in Japan (Study-J1) received PEM 500mg/m2 or 1000mg/
m2 once every 3 weeks. Eligible patients in each of the studies had a 
histologic or cytologic diagnosis of NSCLC and had been previously 
treated. An established pharmacokinetic model was used to estimate 
AUCs from CrCL for patients in Study-W0 that received PEM 500mg/
m2 (N=265) and for patients in Study-J1. AUC was evaluated as a pre-
dictor of clinical efﬁcacy (survival, TTPD, PFS) to identify ERRs. The 
models included previously identiﬁed prognostic factors and inverse of 
mean daily AUC over the treatment period as covariates.
Results: Study-W1 did not show a survival advantage for the 900mg/
m2 (N=293) dose over the 500mg/m2 (N=295) dose. Study-J1 showed 
PEM 500mg/m2 (N=108) and 1000mg/m2 (N=108) to have similar 
efﬁcacy for Japanese patients with previously treated NSCLC. Of 
the efﬁcacy ERRs evaluated for Study-W0 and Study-J1, AUC was 
independently signiﬁcant only for TTPD in Study-W0 and was not 
signiﬁcant for other ERRs in either study (ERRs were not evaluated for 
Study-W1). There is internal consistency between the Study-J1 clinical 
results and the lack of ERRs for that study and external consistency 
between the Study-W1 clinical results and the lack of survival ERR for 
Study-W0.
Conclusion: Based on results available from two large randomized 
clinical trials and the evaluation of exposure-response relationships 
from a third trial, high dose PEM (900mg/mm2 or 1000mg/m2) does not 
offer an efﬁcacy advantage over the currently approved 500mg/m2 dose 
for either western or Japanese patient populations.
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Background: Optimal treatment for elderly patients with NSCLC has 
been under active investigation. This study evaluated the safety and 
initial efﬁcacy of a novel combination regimen of oral ﬂuoropyrimidine 
TS-1 plus gemcitabine (GEM) for elderly patients (pts) with advanced 
NSCLC.
Methods: A phase I/II trial in 11 centers examined TS-1 and GEM 
in pts with age ≥ 70, stage IIIB/IV previously untreated NSCLC. The 
starting dose was 60 mg/day (day 1-14) for TS-1 and 800 mg/m2 for 
GEM (day 8, 15). GEM was increased to 1000 mg/m2 at dose level 2 
and TS-1 was increased to 80 mg/day at dose level 3. Phase II portion 
of the study assessed the efﬁcacy and tolerability of the combination 
regimen at the dose determined in the phase I portion. The primary 
endpoint was objective response rate.
Results: Twenty two pts were enrolled in the phase I portion: 6 pts on 
dose level 1, 10 on dose level 2 and 6 on dose level 3. Median age of 
this group was 75 yrs (range 70-85). Dose limiting toxicities included 
Gr. 4 neutropenia (2 pts) and Gr.3 skin toxicity (4 pts). The recom-
mended dose (RD) was TS-1 60 mg/day and GEM 1000 mg/m2, with 
which 20 pts were subsequently treated in the phase II portion. The me-
dian age of 30 pts treated with the RD was 76 yrs (range 70-85). Grade 
(Gr) 3/4 toxicities include neutropenia (12 pts; 7 with Gr 4), thrombo-
cytopenia (4 pts; 0 with Gr 4), skin toxicity (8 pts), thrombus (1 pt) and 
peumonitis (2 pts). Nine patients (30%, 95% conﬁdence interval [CI] 
= 14 to 46%) had partial responses and 16 (53%, 95% CI = 35 to 71%) 
had stable disease. 
Conclusion: Encouraging antitumor activity and safety of TS-1 plus 
gemcitabine support further development of this combination therapy 
for elderly patients with advanced NSCLC.
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Background: Carboplatin AUC 5 d1-Gemcitabine 1250 mg/m2 d1, 8 
is an approved standard regimen in advanced NSCLC. Hematologic 
toxicity is however frequent; thrombocytopenia is found in more than 
40 % of cases, neutropenia in 20%.
Aim: to investigate in two equally dose-dense regimens, whether the 
toxicity of the Gemcitabine-Carboplatin combination could be reduced 
by administering Carboplatin on day 8 instead of day 1 and without 
change in response rate.
Methods: Patients in arm A are treated with Gemcitabine (1250 mg/m2 
days 1,8) and Carboplatin (AUC 5 day 1) Patients in arm B are treated 
with Gemcitabine (1250 mg/m2 days 1,8) and Carboplatin (AUC 5 day 
8. ) Drugs are administered over a 21-day cycle, on an outpatient basis. 
Toxicity and response are evaluated weekly and every second cycle, 
respectively. 
Statistics: The hypothesis of the study protocol is that regimen B 
shows a decrease in toxicity of 50% without loss of response rates. 
Toxicity is deﬁned as a thrombocytopenia and/or neutropenia grade ı. 
The Bryan and Day design allows to consider both response and toxic-
ity as primary endpoint. With an alpha of 0.10 and a power of 90% the 
sample size was estimated to be 67 patients in each arm. An interim 
analysis was performed after 54 included patients, 27 in each arm. 
Results: A total of 71 patients were enrolled between April 2004 and 
March 2006, before the study was prematurely stopped because data 
showed a statistical signiﬁcant difference in toxicity. Patient and dis-
ease characteristics for the 69 eligible patients are summarized in Table 
1. Toxicity and response are reported in Table 2.
